AstraZeneca initiates Breztri Aerosphere trial, doses first ATHLOS patients

AstraZeneca announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with chronic obstructive pulmonary disease who also have elevated cardiopulmonary risk, irrespective of their exacerbation history. Also, the first participants have been dosed in ATHLOS, a Phase III trial investigating AstraZeneca’s triple therapy BGF vs. ICS/LABA budesonide/formoterol fumarate or placebo on cardiopulmonary parameters including hyperinflation and exercise endurance time, which are associated with health status and survival.